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Abstract
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract.
Most GIST harbor a mutation affecting either the KIT or PDGFRA genes, whereas a small subgroup of tumors is
wild type for mutations.
Mutation of tyrosine kinase receptors is a mechanism of drug resistance that can occur either at the beginning of
treatment (primary resistance) or during the course of therapy (secondary resistance). In addition, mutational status
can predict the response to treatment with tyrosine kinase inhibitors, but the role of mutational status as a
prognostic factor remains controversial.
Evidence of a potential role of mutational status as a prognostic factor has emerged over the past decade. The
presence of KIT exon 11 insertion/deletion involving either one or both Trp557-Lys558 amino acids correlates with
a poorer clinical outcome if compared to patients with tumors wild type for KIT exon 11 mutations. A malignant
clinical behavior has also been documented for KIT exon 13 and KIT exon 9 mutant GIST. Patients with GIST
harboring a PDGFRA mutation seem to have a better prognosis than the others.
The aim of this paper is to review the clinical significance of tyrosine kinase mutational status.
Introduction
Gastrointestinal stromal tumors (GIST) are rare tumors
of the gastrointestinal tract. They arise mostly in the
stomach, followed by the small bowel and colon. Less
frequently they are found in the rectum, esophagus or
in an extra-gastrointestinal location. The biology of
GIST has been widely investigated since Hirota et al. [1]
demonstrated mutations of the KIT receptor as a patho-
genic mechanism of GIST. Other mutations affecting
KIT exons 9, 13 and 17 have been demonstrated [2,3].
About 15% of GIST do not express KIT mutations and
of these approximately 5 to 7% have a mutation affect-
ing the gene encoding for PDGFRA [4]. There is also a
small subgroup of GIST, called wild type (WT), which
do not harbor either KIT or PDGFRA mutations [5].
KIT and PDGFRA are two trans-membrane receptors
that belong to the type III tyrosine kinase family whose
natural ligands are stem cell factor (SCF) and platelet-
derived growth factor (PDGF). Both receptors have a
similar structure with five immunoglobulin-like domains
located on the extracellular side of the receptor, a trans-
membrane portion and an intracellular part containing
two tyrosine kinase domains: one with an adenosine tri-
phosphate (ATP) binding region and the other with a
phosphotransferase region (activation loop). Activation
of the receptor normally occurs with ligand binding
which triggers the receptor dimerization, the autopho-
sphorylation of the tyrosine kinase domain and finally
the activation of substrates like PI3K/Akt, Ras/MAPK
and JAK/STAT. This promotes cell cycle activation, cell
proliferation, and apoptosis inhibition [6,7]. Several
gain-of-function mutations of KIT and PDGFRA affect-
ing different exons have been reported [8,9].
The correlation between KIT and PDGFRA muta-
tional status and the response to tyrosine kinase inhibi-
tors and their role in primary and secondary resistance
has been widely investigated [10,11].
The aim of this paper is to review the clinical signifi-
cance of mutational status and its value as a predictive/
prognostic factor in limited and metastatic disease.
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Prognostic value of mutational analysis in
localized GIST
Whenever possible surgery is the best treatment for
GIST. Unfortunately, even after radical surgery the five-
year survival rate is about 54% and the disease-free sur-
vival (DFS) is 45% [12,13]. Tumor size (≥10 cm), mitotic
rate (≥5/50HPF) and tumor location are known to be
independent prognostic factors for shorter DFS in fully
resected GIST patients. In 2002 Fletcher et al. developed
a risk stratification for primary tumors (National Health
Institute -NHI classification), considering tumor size
and mitotic count as predictive factors of aggressive
behavior [6]. In 2006 Miettinen and Lasota analyzed the
follow-up data from more than 1600 fully resected
tumors and, on the basis of their results, revised the
NIH classification adding primary tumor location as an
important prognostic factor to identify the class of risk
for resected primary GIST [7]. According to the latest
classification, the risk of recurrence goes from being
very low for small tumors (≤ 2 cm) with low mitotic
rate (≤5/50HPF) and gastric location, to close to 90% for
large tumors (> 10 cm) with high mitotic rate (≥ 5/
50HPF) and small intestinal location [7]. Due to a wide
spectrum of behavior, it is crucial to find further factors
that can have a prognostic value in predicting the risk
of relapse for fully resected tumors. The importance of
the mutational status of KIT and PDGFRA as a prog-
nostic factor remains controversial, although its predic-
tive value on tyrosine kinase inhibitors response is now
clearer.
Early evidence of a potential role of mutational status
as a prognostic factor appeared in the late nineties,
when different groups observed a correlation between
KIT exon 11 mutations and a poorer clinical outcome
compared to patients with tumors WT for KIT exon 11
mutations. Ernst et al. identified a subgroup of 13 KIT
exon 11 mutant tumors in a larger group of 35 GIST
patients and observed that the mutation was associated
with a shorter survival rate (p = 0.001). No correlation
between mutations, tumor size or mitotic index was
observed [14]. When GIST were still classified as malig-
nant or benign, KIT exon 11 mutations were noticed to
be more common in the malignant subtype [15]. In
addition, a study of 124 GIST patients showed a clear
difference in prognosis for patients with or without KIT
exon 11 mutations and a subdivision into mutation-
positive and mutation-negative patients was proposed
[16]. However, in 1999 only KIT exon 11 was studied
and the prognostic role of mutations could not be
evaluated.
Malignant clinical behavior was also documented for
KIT exon 9 and KIT exon 13 mutant GIST [16-18], and
for the first time the association between KIT exon 9
mutation and small intestinal location was reported [17].
In general, all the cited studies focused on KIT exon 11
mutations, whereas few dealt with KIT exon 9, 13 or 17
mutations. The first study to screen KIT exons 9, 11, 13,
and 17 for mutations was performed in 2002 by Singer et
al.: 44 tumors out of 48 harbored a KIT mutation. They
found a KIT mutation was associated with a poor clinical
outcome and they also hypothesized that specific KIT
mutations could have a prognostic value. The multivari-
ate analysis showed that patients with GIST harboring a
KIT deletion/insertion had a significantly shorter recur-
rence-free survival (RFS) than patients with tumors har-
boring a KIT exon 11 missense mutation, which was
more common in favorable-outcome, low-grade GIST
[19]. A larger study on 120 patients identified two small
subgroups with different clinical outcomes [20]. The first
small subgroup of eight cases had a more favorable prog-
nosis and consisted of tumors harboring an insertion of
6-20 amino acids representing intra-tandem-duplications
(ITDs) at the 3’ end of exon 11. All eight tumors were
located in the stomach, had a spindle cell morphology,
and a low mitotic count. Patients were all older than 60
years of age and seven out of eight were female. The sec-
ond subgroup included 13 tumors that harbored a KIT
exon 9 mutation, had a predominant small intestinal
location and a poorer outcome compared to the other
patients [18].
In 2005 a large retrospective study by Kim et al.
enrolled 86 patients who underwent radical resection of
localized GIST [21]. Sixty-one GIST had a mutation of
KIT exon 11 and three had a mutation of KIT exon 9.
KIT exons 13 and 17 were screened but no mutations
were found in 22 tumors. The class of risk considering
tumor size and the mitotic rate was identified for all the
patients. All three KIT exon 9 mutations were insertions
of six nucleotides, resulting in duplication of Ala502-
Tyr503, two patients had a high risk GIST but all three
KIT exon 9 mutants had a relapse of the disease. The
most common mutation of KIT exon 11 was a deletion
that involved codons between 550 and 570. Three IDTs
were also found in tumors with spindle cell morphology,
no mitotic activity and benign clinical behaviors. The
patients were all female and were all alive and relapse-
free after 24-80 months of follow-up, despite the tumor
risk class. In general the five-year RFS for patients
whose tumor harbored a KIT mutation was significantly
shorter than for patients with tumors without KIT
mutations. KIT mutations were also observed to be
associated with a higher mitotic rate, which together
with tumor size was already a known negative prognos-
tic factor [21].
Wardelmann et al. correlated the mutational status of
55 GIST and the clinical outcome. The size of 50
tumors was known, 21 tumors had a diameter ≤ 5 cm
and none of them had evidence of metastasis, 29 tumors
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had a diameter larger than 5 cm and 15 of them had a
metastatic spread. A mutation affecting 557 and/or 558
codons of KIT exon 11 was found in 13 of 15 metastatic
tumors and in only two of the nine mutated and not
metastatic tumors. These results suggested that muta-
tions involving 557 and/or 558 codons could be used as
an additional parameter to estimate poor survival [22].
Subsequent studies confirmed the hypothesis of an asso-
ciation between a KIT exon 11 insertion/deletion invol-
ving either one or both Trp557-Lys558 amino acids and
a poor clinical outcome [23,24]. DeMatteo et al. studied
a series of 127 non-metastatic GIST patients who
underwent complete tumor resection and were all
entered in a follow-up program [24]. As expected,
tumor size, mitotic rate and location predicted the RFS
in the multivariate analysis. Only in the univariate analy-
sis did KIT exon 9 mutations and KIT exon 11 deletions
involving codons 557 and/or 558 correlate with a higher
rate of recurrence, whereas patients with point of muta-
tion or insertion of KIT exon 11 had a lower rate of
recurrence, and patients with WT tumors had an inter-
mediate outcome. Only four patients had a GIST har-
boring a mutation of KIT exon 9, they all had a disease
recurrence but the number was too small to hypothesize
a prognostic value [24].
The Spanish Group for Sarcoma Research (GEIS)
selected 162 patients who underwent complete resection
of localized GIST between 1994 and 2001. All the
tumors were ≥ 2 cm and KIT positive at immunohisto-
chemical analysis. They evaluated the prognostic value
of RFS prediction of different KIT and PDGFRA muta-
tions. The results were analyzed when the median fol-
low-up was 42 months and at that point 41 of the 162
patients experienced a disease recurrence and the five-
year RFS was 68%. According to the NIH and the Miet-
tinen-Lasota risk classifications, tumors with a high
mitotic count and large dimensions had a significantly
shorter RFS. In addition, following the Miettinen-Lasota
revised risk classification the RFS was significantly
shorter for patients whose primary tumor was located in
the small bowel compared to patients whose primary
tumor was located in the stomach. A very interesting
statistic was the higher recurrence rate (5-year RFS 57%
± 13%) of tumors harboring mutations of the KIT gene,
rather than tumors without KIT mutations (5-year RFS
80% ± 11%). In the univariate analysis, patients with
deletions involving codons 557 and/or 558 of KIT exon
11 had a less favorable outcome than patients with dif-
ferent mutations or without KIT mutations. The pre-
sence of deletions involving codons 557 and/or 558 of
KIT exon 11 was also significantly associated with a
higher rate of recurrence in the multivariate analysis
together with size, mitotic count and high cellularity,
which are known prognostic factors [25].
After a longer follow-up, the data from the same group
of 162 patients were analyzed again by the Spanish
Group for Sarcoma Research (GEIS). The first analysis
demonstrated that the mutations within KIT exon 11
involving codons 557 and/or 558 have a prognostic rele-
vance. The objective of the new study was to demonstrate
if critical deletions still are an independent prognostic
factor after a longer follow-up, and if there were any
time-related prognostic factors for RFS. When the analy-
sis was performed the median follow-up was 84 months,
the factors assessed were the class of risk (both classifica-
tions NIH and Miettinen-Lasota were considered) and
the type of mutation. Mutations were also classified as
deletions of codons 557 and/or 558 of KIT exon 11 (criti-
cal mutations), non-deletion-type mutations of KIT exon
11 (NDTM) which included missense mutations and
insertions, and other deletions of KIT exon 11. Results
showed that, for the first four years after surgery and for
the entire seven-year follow-up the presence of critical
deletions belonging to a high-risk category were indepen-
dent prognostic factors for RFS. In the first 4 years after
surgery only the high-risk category of the Miettinen-
Lasota classification and NDTM were independent prog-
nostic factors for RFS. In fact, the presence of critical
mutations could be useful to identify a subset of patients
with a higher risk of relapse in the first four years after
surgery, whereas the presence of NDTM could identify a
subset of patients more likely to experience a relapse
beyond three or four years after surgery [26].
A better outcome and a lower chance of metastasis
seem to be associated with PDGFRA exon 18 mutations
[27]. Lasota et al. screened 1000 GIST for KIT exon 11
mutations, KIT exon 9 (only the non-gastric tumors)
and PDGFRA exons 18 and 12. PDGFRA mutant
tumors had a prevalent gastric location, epithelioid mor-
phology (pure or prevalent) and low mitotic count. Of
1000 GIST, a PDGFRA exon 18 mutation was found in
122 of the 346 gastric tumors and only two of the 75
small intestinal tumors. Ten of the 170 gastric tumors
and one of the 54 small intestinal tumors had a
PDGFRA exon 12 mutation. One hundred and five of
those had ≤5 mitosis/50HPF, and 40 had no mitotic
activity. Clinical data were available for 91 out of 128
PDGFRA exon 18 mutant tumors. After a median fol-
low-up of 135 months, 41 were alive and with no evi-
dence of disease, 24 had died from other causes, 16 had
died for unknown causes, and ten had a progressive dis-
ease. Seven died of the disease and three were still alive
at the end of the follow-up (370 months). The authors
concluded that 83% of GIST with PDGFRA mutations
have a good prognosis [27]. The same group of scien-
tists demonstrated later that PDGFRA exon 14 mutant
GIST are mostly gastric, have epithelioid morphology
and benign clinical behavior [28].
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Predictive value of response to therapy
Although the role of KIT/PDGFRA mutational status as
a prognostic factor is controversial, it is well known to
predict the response to treatment with tyrosine kinase
inhibitors.
The mutation of tyrosine kinase receptors is a
mechanism of drug resistance occurring either at the
beginning of treatment (primary resistance) or during
the course of therapy (secondary resistance).
The first study that showed the correlation between
the response to imatinib at a dose of 400 mg/day and
mutational status in GIST was performed by Heinrich et
al. One hundred and twenty-seven patients with meta-
static GIST received imatinib, 71 had a tumor with a
mutation of KIT exon 11, 23 of KIT exon 9, two of KIT
exon 13 and KIT exon 17; PDGFRA exon 18 was
mutated in six cases and nine tumors were WT. The
clinical response varied considering the different muta-
tions, the stronger predictor of response being any KIT
exon 11 mutation. The 87.5% of patients whose tumor
had a KIT exon 11 mutation achieved a partial response,
whereas only 47.8% of patients whose tumor had a KIT
exon 9 mutation had a partial response [10].
The European Organization for Research and Treat-
ment of Cancer (EORTC) phase I and II studies [29-31]
enrolled patients with metastatic GIST and tested the
safety of imatinib given at a dose of 400 mg/day or 800
mg/day and investigated its activity. The results of the
mutational analysis performed on 37 tumor specimens
showed a further correlation between certain mutations
and their response to imatinib. Of the 37 tumors, 24
had a KIT exon 11 mutation, four had a KIT exon 9
mutation, one had a KIT exon 13 mutation and two had
a PDGFRA exon 18 mutation. Patients whose tumors
had a KIT exon 11 mutation had a higher partial
response rate than the others and patients whose
tumors harbored a KIT mutation enjoyed a longer med-
ian survival time and a lower recurrence rate [32].
Two recent randomized phase III studies compared
the outcome of metastatic GIST patients treated with
imatinib 400 mg/day or 800 mg/day. The EU-AUS trial
(EORTC and Australian Gastro-Intestinal Trial Group)
enrolled 946 patients with metastatic GIST between
2001 and 2002. The primary endpoint of the study was
RFS and the patients were randomized to receive imati-
nib at the two doses with the possibility of cross over to
the higher doses in case of progressive disease [33].
Mutational analysis was performed in 377 cases: 248
harbored a KIT exon 11 mutation, 58 a KIT exon 9
mutation, six a KIT exon 13 mutation, and three a KIT
exon 17 mutation, whereas ten tumors harbored a
PDGFRA exon 18 mutation. Patients with tumors
expressing any mutation of KIT exon 11 had a higher
response rate and a longer median survival than patients
whose tumors harbored KIT exon 9 mutations or whose
tumors were WT. Once the KIT exon 11 tumor mutant
group was divided into subgroups, the statistical analysis
revealed a poorer outcome for patients whose tumor
had large exon 11 deletions, especially if involving
codons 577-579, this may be due to the conformational
change in the receptor. In the group of KIT exon 9
mutant tumors the response rate was significantly
higher for patients enrolled in the 800 mg/day arm [33].
The other phase III study (US-CDN) was conducted
by the Southwest Oncology Group (SWOG), Cancer
and Leukemia Group B (CALGB), National Cancer
Institute of Canada (NCI-C) and Eastern Cooperative
Oncology Group (ECOG) [34]. This study, which had
OS as primary endpoint, enrolled 746 patients with
advanced GIST and randomized them to receive imati-
nib 400 mg/day or 800 mg/day equal to the EU-AUS
trial. Of the total, 428 tumors were screened for KIT
and PDGFRA mutations. The analysis disclosed a KIT
exon 11 mutation in 283 cases, a KIT exon 9 mutation
in 32 cases, whereas 67 tumors were WT. Patients were
randomly assigned to receive imatinib at the daily dose
of 400 mg or 800 mg. The time to progression (TTP)
did not change for patients with any KIT exon 11 muta-
tion or WT GIST. Patients with a KIT exon 9 mutation
had a significantly higher rate of response if treated with
imatinib at the daily dose of 800 mg, but there was no
difference in time to progression and overall survival
between the two groups. No differences were observed
for KIT exon 11 mutant or WT GIST treated with 400
or 800 mg/day. Instead, any KIT exon 11 mutation was
associated with a better outcome in patients with
advanced GIST treated with imatinib compared to
patients with KIT exon 9 mutations or WT tumors [34].
The Gastrointestinal Stromal Tumor Meta-Analysis
Group (MetaGIST) re-analyzed and compared the data
from the EU-AUS and the US-CDN studies to confirm
the results, validate the suggested prognostic and predic-
tive factors and to explain the differences between
results in the two studies by reviewing the characteris-
tics of the two populations.
A small advantage on PFS was observed for the high-
dose arm in both studies, no difference in overall survi-
val (OS). Prognostic factors for PFS and OS were then
considered. Mutational status was a significant prognos-
tic factor (p < 0.0001) for PFS, and patients with KIT
exon 11 mutation had a more favorable prognosis than
those with exon 9 mutation or WT.
Exon 9 mutation was the only significant predictive
factor for a benefit of high-dose therapy. Patients with
KIT exon 9 mutations treated with imatinib 800 mg/day
had a significantly longer PFS than the others and the
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estimated rate of progression or death was also signifi-
cantly decreased (p = 0.017) [35].
A further phase III trial compared two doses of imati-
nib for treatment of unresectable advanced GIST. To
investigate the influence of mutational status on imati-
nib response, 128 GIST specimens from those patients
were screened for KIT and PDGFRA mutations. The
estimated median survival was 63 months for patients
whose tumor harbored a KIT exon 11 mutation, 44
months for patients whose tumors harbored a KIT exon
9 mutation and 26 months in case of other mutations
or WT GIST. In addition, a mutation within KIT exon
11 was associated with a better outcome for the first 30
months of therapy [36].
Fewer studies have defined the role of mutational sta-
tus as a prognostic and predictive factor in the adjuvant
setting. It is well known that adjuvant therapy with ima-
tinib is associated with a longer RFS [37]. For this pur-
pose 713 patients who underwent complete resection of
a primary GIST were enrolled on the Z9001 study. All
primary tumors were ≥3 cm and expressed KIT. Patients
were randomized to receive imatinib 400 mg/day for
one year or a placebo. Tumor size, mitotic index and
mutational status were available for 513 patients. After a
median follow-up of 20 months, the two-year RFS was
74% in the placebo arm vs. 91% in the imatinib arm.
The two-year RFS for patients with KIT exon 11 muta-
tion was 65% vs. 91% (placebo and imatinib arm respec-
tively p < 0.0001), 76% vs. 100% for the PDGFRA
mutation (p < 0.01), whereas there were no difference in
overall RFS for KIT exon 9 mutation, but the one-year
RFS was shorter for patients in the placebo arm (80%)
than in the imatinib arm (100%). This study showed
that mutational status together with pathological fea-
tures have a prognostic and predictive value for RFS
after complete surgical resection of primary GIST [38].
Secondary resistance occurs after a median period of
24 months of treatment with imatinib. There are several
mechanisms involved in resistance like the activation of
an alternative downstream signaling pathway such as
AKT/mTOR, the activation of an alternate tyrosine
kinase receptor and the loss of KIT expression, the
genomic amplification of KIT, and the gain of new KIT/
PDGFRA mutations [39]. New KIT/PDGFRA mutations
are currently considered the most important and the
most common mechanism [40-43].
Mutational analysis performed on tissue specimens
from resistant lesions disclosed secondary acquired
mutations developed during imatinib therapy. The fre-
quency of secondary mutations is over 50% in those
tumors with primary KIT exon 9 or 11 mutations. Sec-
ondary mutations are single substitutions and occur in
different exons but on the same allele of the primary
mutation. Similar to chronic myeloid leukemia, acquired
imatinib resistant mutations affect the tyrosine kinase
domain and the activation loop, encoded by exons 13,
14 and 17 respectively [9,40,43-47]. The most common
secondary mutation is the V654A, mainly found in
GIST harboring an exon 11 primary mutation [48].
PDGFRA secondary mutations are rare. The D842V was
identified in one patient with primary mutation V561D,
which is known to be associated with imatinib resistance
[48]. In general, secondary mutations were detected only
in progressive nodules and not in non-progressive ones
[46,49]. In addition, patients with WT GIST do not
develop secondary mutations [46]. A recent study by
Liegl et al. analyzed 53 metastases from 14 patients after
imatinib or sunitinib treatment failure. Primary tumors
included GIST with classical features (KIT positive, and
mutated on KIT exons 9, 11, or 13), but also KIT nega-
tive tumors, GIST with unusual morphology, and KIT/
PDGFRA WT GIST. Secondary KIT mutations were
found in nine out of 11 GIST with KIT primary muta-
tion. Two to five different mutations were found in dif-
ferent metastases I six out of nine patients, and in three
out of nine patients two mutations were found in one
or more tumor samples. Five recurrent points of muta-
tion were located in the KIT tyrosine kinase domain
and in the ATP activation loop. No secondary mutations
were found in KIT/PDGFRA WT GIST or in those with
unusual morphology [47].
Sunitinib inhibits double mutant GIST and the
response to therapy is influenced by the mutational status
[11,50]. Seventy-eight imatinib resistant patients were
treated with sunitinib, 58% of patients had tumors har-
boring KIT exon 9 mutations, 34% had tumors harboring
KIT exon 11 mutations, and 56% of tumors were WT.
Results showed a significantly longer progression-free
survival and overall survival for patients with primary
KIT exon 9 mutations (p < 0.0005) or WT (p < 0.0356)
than for those with KIT exon 11 mutations. In addition,
patients whose tumor expressed a secondary mutation
affecting exons 13 or 14 had a better outcome than those
whose tumor had a KIT exon 17 or 18 mutation [11].
In addition to the cellular and mutational profile of
the disease, broad variations of imatinib plasma levels
have been monitored in GIST patients [51,52]. The
decrease of imatinib bioavailability during chronic thera-
pies should be considered a further possible mechanism
of resistance. Recently Demetri et al. studied the imati-
nib pharmacokinetic and pharmacodynamic profiles in
advanced GIST patients to detect possible correlations
between the imatinib plasma concentrations and clinical
outcome. They observed that patients with the lowest
imatinib serum levels had the lowest overall response
rate and the shortest time to progression [51,52].
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Conclusions
The value of mutational status as a predictive and prog-
nostic factor for RFS in metastatic GIST treated with
imatinib is clear. What is now becoming more evident is
its potential role as a predictive and prognostic factor
for resected GIST treated with imatinib. Tumors har-
boring KIT exon 11 mutations have a better outcome
under imatinib treatment at a dose of 400 mg/day than
tumors harboring different mutations, and KIT exon 9
mutant tumors have a longer RFS if treated with the
high dose of imatinib, corresponding to 800 mg/day.
Patients with KIT exon 9 mutant tumors achieve a bet-
ter response to sunitinib, than those with exon 11 muta-
tions. The PDGFRA exon 18 D842V point mutant
activates PDGFRA both in vitro and in vivo [10,50] and
is also imatinib resistant in vivo and in vitro [30,53,54],
whereas other mutations affecting exon 18 (D846Y,
N848K, Y849K and HDSN845-848P) are imatinib sensi-
tive [53].
In the adjuvant setting, available data show that muta-
tional status can be considered a predictive and prog-
nostic factor for GIST patients treated with imatinib
after radical surgery [38].
Dei Tos et al. recently reviewed a series of 929
untreated GIST to correlate the natural history of dis-
ease with pathological features, but the mutational status
of tumors was not available [55]. Tumor size (≥10 cm),
mitotic rate (≥5/50HPF) and tumor location are the
only recognized independent prognostic factors for
GIST patients [11,12], but unfortunately it is still
unclear whether or not mutational status could be an
independent prognostic factor for disease recurrence in
untreated patients. It would be useful to be able to
study mutational status on a large population of
untreated GIST but this has become more difficult since
evidence emerged of a longer RFS following adjuvant
treatment with imatinib.
Lastly, knowledge of the predictive and prognostic
value of mutational status could lead physicians to estab-
lish the dose of imatinib, identify those patients who
would not benefit from imatinib treatment (PDGFRA
exon 18 D842V mutant tumors are imatinib resistant),
chose a second line therapy, and evaluate the different
risk of relapse during follow-up. These data emphasize
that mutational status must play a predominant role in
the clinical management of patients and that new find-
ings are necessary to establish the mechanisms responsi-
ble for imatinib resistance in specific subsets of tumors
like PDGFRA D842V mutant and WT GIST.
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